• In early June 2026, Teva Pharmaceutical Industries reported new clinical data from three studies showing that AUSTEDO and AUSTEDO XR improved tardive dyskinesia symptoms, daily functioning, and diagnosis rates when presented at Psych Congress Elevate in Las Vegas.
• The findings, including real-world evidence from the IMPACT-TD Registry and long-term outcomes from the RIM-TD study, suggest that sustained treatment and caregiver education can meaningfully enhance recognition and management of this chronic movement disorder.
• We’ll now examine how Teva’s new real-world and long-term AUSTEDO data, particularly sustained TD improvement, could shape its investment narrative.

Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Teva Pharmaceutical Industries Investment Narrative Recap

To own Teva today, you need to believe its pivot toward higher margin branded drugs like AUSTEDO can offset a flat generics base while heavy debt is steadily reduced. The new AUSTEDO tardive dyskinesia data supports the product’s clinical profile, but it does not materially change the near term focus on AUSTEDO pricing risk under the Inflation Reduction Act or the need to keep improving cash flow to manage net debt above US$15 billion.

Among recent announcements, the launch of AHZANTIVE, an Eylea biosimilar, in key European markets looks most connected to Teva’s broader growth story. It shows how biosimilars might support the generics segment, which consensus expects to remain flat, and could help diversify revenue away from the small group of branded drivers that currently concentrate Teva’s growth and regulatory risks.

Yet, while the AUSTEDO data may support the bulls who see earnings rising toward US$3.1 billion, investors should also be aware of how...

Teva Pharmaceutical Industries’ narrative projects $18.1 billion revenue and $2.7 billion earnings by 2029. This requires 1.5% yearly revenue growth and about a $1.1 billion earnings increase from $1.6 billion today.

Uncover how Teva Pharmaceutical Industries' forecasts yield a $41.27 fair value, a 23% upside to its current price.

Exploring Other Perspectives

The most optimistic analysts were already assuming Teva could lift earnings to about US$3.1 billion by 2029, but this AUSTEDO update might either reinforce that view or highlight how dependent it is on one branded franchise that could face pricing and reimbursement pressure.

Explore 3 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth just $41.27!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.